The Global Veterinary Endocrinology Market size is expected to reach $482.2 million by 2031, rising at a market growth of 6.6% CAGR during the forecast period.
North America has a significant population of companion animals, including dogs, cats, and other pets. Thus, the North America region acquired 39% revenue share in the market 2023. The high prevalence of pets in households contributes to a larger pool of potential patients requiring specialized veterinary care, including endocrinology services. Pets in North America are often considered family members, leading to greater investments in their health and well-being. Pet owners prioritize preventive healthcare, advanced diagnostics, and specialized treatments, including veterinary endocrinology, to ensure their pets lead healthy and comfortable lives.
There’s growing awareness among pet owners and veterinarians about various endocrine disorders that affect animals, such as diabetes mellitus, thyroid disorders, adrenal gland disorders, and reproductive hormone imbalances. This awareness leads to more animals being diagnosed and treated for these conditions.
Additionally, the global pet population, including dogs, cats, and exotic pets, continues to increase. This demographic trend directly correlates with a higher incidence of pet health issues, including endocrine disorders such as diabetes mellitus, thyroid disorders, and adrenal gland disorders. Therefore, increasing pet ownership and expenditures on pet healthcare drive the market's growth.
However, veterinary diagnostics and treatments for endocrine disorders can be expensive, especially when multiple diagnostic tests, specialized imaging studies, and ongoing treatment regimens are required. This can create financial constraints for pet owners, leading to hesitation or delay in seeking veterinary care. Thus, the high cost of diagnostic and treatment procedures impedes growth.
North America has a significant population of companion animals, including dogs, cats, and other pets. Thus, the North America region acquired 39% revenue share in the market 2023. The high prevalence of pets in households contributes to a larger pool of potential patients requiring specialized veterinary care, including endocrinology services. Pets in North America are often considered family members, leading to greater investments in their health and well-being. Pet owners prioritize preventive healthcare, advanced diagnostics, and specialized treatments, including veterinary endocrinology, to ensure their pets lead healthy and comfortable lives.
There’s growing awareness among pet owners and veterinarians about various endocrine disorders that affect animals, such as diabetes mellitus, thyroid disorders, adrenal gland disorders, and reproductive hormone imbalances. This awareness leads to more animals being diagnosed and treated for these conditions.
Additionally, the global pet population, including dogs, cats, and exotic pets, continues to increase. This demographic trend directly correlates with a higher incidence of pet health issues, including endocrine disorders such as diabetes mellitus, thyroid disorders, and adrenal gland disorders. Therefore, increasing pet ownership and expenditures on pet healthcare drive the market's growth.
However, veterinary diagnostics and treatments for endocrine disorders can be expensive, especially when multiple diagnostic tests, specialized imaging studies, and ongoing treatment regimens are required. This can create financial constraints for pet owners, leading to hesitation or delay in seeking veterinary care. Thus, the high cost of diagnostic and treatment procedures impedes growth.
Driving and Restraining Factors
Drivers- Rising prevalence of endocrine disorders in animals
- Expansion of veterinary endocrinology services
- Increasing pet ownership and expenditure on pet healthcare
- High cost of diagnostic and treatment procedures
- Complexity of hormonal disorders
- Growing livestock industry
- Integration of holistic care approaches
- Limited access to specialized services
- Compliance and long-term management
Route of Administration
Based on route of administration, the market is divided into oral and others. In 2023, the oral segment garnered 57.7% revenue share in the market. Oral medications are typically easier to administer than other forms, such as injections or transdermal treatments.Animal Type Outlook
On the basis of animal type, the market is segmented into dogs, cats, and others. In 2023, the cats segment attained 30.7% revenue share in the market. The cat population, like the dog population, is aging due to advancements in veterinary medicine and nutrition.
Application Outlook
Based on application, the market is categorized into pancreatic disorders and others. In 2023, the pancreatic disorders segment registered 53.2% revenue share in the market. Pancreatic disorders often present with nonspecific clinical signs, making accurate diagnosis challenging.Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2023, the Europe region generated 29.9% revenue share in the market. European veterinarians undergo rigorous training and education, often specializing in specific fields such as endocrinology.List of Key Companies Profiled
- Dechra Pharmaceuticals PLC (EQT AB)
- Elanco Animal Health Incorporated
- Merck & Co., Inc.
- Boehringer Ingelheim International GmbH
- Zoetis, Inc.
- LLOYD, Inc.
- Covetrus, Inc. (Clayton, Dubilier & Rice, LLC)
- Mars, Inc. (Antech Diagnostics, Inc)
Market Report Segmentation
By Route of Administration- Oral and
- Other routes
- Dogs,
- Cats, and
- Other Animals
- Pancreatic Disorders, and
- Other Disorders
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Global Veterinary Endocrinology Market by Route of Administration
Chapter 5. Global Veterinary Endocrinology Market by Animal Type
Chapter 6. Global Veterinary Endocrinology Market by Application
Chapter 7. Global Veterinary Endocrinology Market by Region
Chapter 8. Company Profiles
Companies Mentioned
- Dechra Pharmaceuticals PLC (EQT AB)
- Elanco Animal Health Incorporated
- Merck & Co., Inc.
- Boehringer Ingelheim International GmbH
- Zoetis, Inc.
- LLOYD, Inc.
- Covetrus, Inc. (Clayton, Dubilier & Rice, LLC)
- Mars, Inc. (Antech Diagnostics, Inc)
Methodology
LOADING...
